BRIC markets now account for 20%-30% of pharma profits, Cegedim reports

A new white paper, titled Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape, highlights first-hand market insights from Cegedim Relationship Management experts in the BRIC countries (Brazil, Russia, India and China). The report outlines the critical relationship between evolving BRIC health care climates and pharmaceutical markets; and the best strategies to boost growth in each of the emerging markets.

The stakes are rising for improving commercial performance in emerging markets. Five years ago, emerging markets were responsible for just 5% of pharmaceutical companies’ profits; today, they make up 20%-30% of profits. Shifts in the BRIC landscape will prompt companies to optimize their commercial strategies with a better understanding of local markets and stakeholder networks.

“Our proven legacy within BRIC markets empowers us to deliver the most relevant insights on industry trends and challenges facing each pharmaceutical target country,” said Laurent Labrune, chief executive of Cegedim Relationship Management, adding: “Our on-site presence in each BRIC country enables us to furnish companies with the game-changing industry knowledge required to innovate beyond the challenges of rapidly evolving health care environments.”